Loading
Latent Labs is an artificial intelligence research laboratory and biotechnology company founded in 2023 and based in London, with an additional office in San Francisco. The company focuses on making biology programmable by integrating computational biology, generative AI, and molecular engineering. With a total funding of $50 million, including a significant Series A round, Latent Labs aims to accelerate the development of AI foundation models and foster partnerships within the biotech and pharmaceutical sectors. The flagship product, the Latent-X platform, is a web-based tool designed for de novo protein and antibody design. It allows users to upload target proteins and define desired epitopes, generating lab-ready protein binders and full all-atom structures. Latent Labs also provides advanced generative AI capabilities to help organizations design new antibodies, optimize enzymes, and advance genetic engineering. The company serves a diverse range of clients, including biotechnology and pharmaceutical companies, healthcare partners, researchers, and sustainability organizations, with a mission to automate and enhance the drug discovery process.